论文部分内容阅读
为探讨ＨＣＶ／ＨＢＶ 复合疫苗的可行性，将合成的丙型肝炎病毒（ＨＣＶ）复合多表位抗原基因ＰＣＸ与ＨＢｓＡｇ 基因连接成ＰＣＸＳ基因，与β－半乳糖苷酶（ＧＺ）基因融合后在大肠杆菌及减毒鼠伤寒沙门氏菌中获得表达．目的蛋白ＧＺ－ＰＣＸＳ可被抗－ＨＢｓ 及抗－ＨＣＶ 抗体所特异识别．ＧＺ－ＰＣＸＳ抗原皮下注射免疫ＩＣＲ小鼠后，诱发了较高水平的抗－ＧＺ－ＰＣＸＳＩｇＧ反应．构建的重组减毒鼠伤寒沙门氏菌ＳＬ３２６１（ｐＷＲ／ＰＣＸＳ）口服免疫小鼠后，诱发了高水平的ＣＤ８＋ Ｔ细胞增殖反应及抗ＧＺ－ＰＣＸＳＩｇＧ反应．所有免疫小鼠均未见明显的毒副作用．该研究揭示，ＨＣＶ／ＨＢＶ 复合抗原可诱发特异性体液免疫及细胞免疫应答，而活菌苗口服可能是理想的免疫途径，为ＨＣＶ／ＨＢＶ 双价疫苗研究提供了一定的理论及实验依据．
In order to explore the feasibility of HCV / HBV combination vaccine, PCX and HBsAg genes were cloned into PCXS gene and fused with β-galactosidase (GZ) Escherichia coli and attenuated Salmonella typhimurium expression. The target protein GZ-PCXS can be specifically recognized by anti-HBs and anti-HCV antibodies. Subcutaneously immunization of ICR mice with GZ-PCXS antigen induced a higher level of anti-GZ-PCXSIgG response. The constructed recombinant attenuated Salmonella typhimurium SL3261 (pWR / PCXS) orally immunized mice, induced a high level of CD8 + T cell proliferation and anti-GZ-PCXSIgG response. All immunized mice showed no obvious side effects. The study revealed that HCV / HBV composite antigen can induce specific humoral and cellular immune responses. However, oral administration of live bacterins may be an ideal route of immunization and provide some theoretical and experimental evidences for the study of HCV / HBV bivalent vaccine.